A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)

C. J. Hoimes, C. Albany, J. Hoffman-Censits, M. T. Fleming, E. Trabulsi, J. Picus, C. Cary, M. O. Koch, R. Walling, W. Kelly, J. L. Godwin, M. Cooney, P. Fu, A. Nelson, K. Patel, C. Eitman, T. Breen, A. Neal, H. Kaimakliotis

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)viii726
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Hoimes, C. J., Albany, C., Hoffman-Censits, J., Fleming, M. T., Trabulsi, E., Picus, J., Cary, C., Koch, M. O., Walling, R., Kelly, W., Godwin, J. L., Cooney, M., Fu, P., Nelson, A., Patel, K., Eitman, C., Breen, T., Neal, A., & Kaimakliotis, H. (2018). A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii726. https://doi.org/10.1093/annonc/mdy424.039